Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Resomelagon in Patients With Dengue Infection
NCT06917001Phase 2Recruiting
- Sponsor
- Universidade Federal de Minas Gerais
- Start
- Mar 2026
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in dengue fever comparing Resomelagon with Placebo (2 arms). Primary endpoints: Safety of Resomelagon at 28 days and Duration of illness at 10 days. Started Mar 2026; status: recruiting.
02
Drugs
resomelagon
03
Conditions
dengue fever
Beyond the preview
Go deeper on NCT06917001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06917001.